Latest & greatest articles for influenza

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on influenza or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on influenza and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for influenza

121. Expert Opinion on neuraminidase inhibitors for prevention and treatment of influenza (Feb 2016)

Expert Opinion on neuraminidase inhibitors for prevention and treatment of influenza (Feb 2016) DRAFT SCIENTIFIC ADVICE FOR CONSULTATION ECDC PRELIMINARY SCIENTIFIC ADVICE Expert Opinion on neuraminidase inhibitors for prevention and treatment of influenza Review of recent systematic reviews and meta-analyses ii This report of the European Centre for Disease Prevention and Control (ECDC) was coordinated by Pasi Penttinen and Kari Johansen. Contributing authors Emmanuel Robesyn, Eeva Broberg (...) under copyright and cannot be used for purposes other than this publication without the express permission of the copyright holder. SCIENTIFIC ADVICE Expert Opinion on Neuraminidase inhibitors for prevention and treatment of influenza iii Contents Abbreviations iv Glossary v Executive summary 1 Background 3 Request for ECDC Expert Opinion 5 Methods 6 Results and discussion 8 General characteristics of the systematic reviews and meta-analyses reviewed by ECDC expert group 8 Treatment of outpatients

European Centre for Disease Prevention and Control - Expert Opinion2016

122. Tool for Influenza Pandemic Risk Assessment (TIPRA)

Tool for Influenza Pandemic Risk Assessment (TIPRA) WHO IRIS: Tool for Influenza Pandemic Risk Assessment (TIPRA) Browse Related links Files in This Item: File Description Size Format 1.12 MB Adobe PDF Title: Tool for Influenza Pandemic Risk Assessment (TIPRA) Authors: Issue Date: 2016 Publisher: World Health Organization Place of publication: Geneva Language: English Description: 60 p. Subject: Gov't Doc #: WHO/OHE/PED/GIP/2016.2 URI: Appears in Collections: Items in WHO IRIS are protected

WHO2016

123. WHO Global Action Plan for Influenza Vaccines report on online survey for the GAPIII consultation

WHO Global Action Plan for Influenza Vaccines report on online survey for the GAPIII consultation WHO IRIS: WHO Global Action Plan for Influenza Vaccines report on online survey for the GAPIII consultation Browse Related links Files in This Item: File Description Size Format 371.09 kB Adobe PDF Title: WHO Global Action Plan for Influenza Vaccines report on online survey for the GAPIII consultation Authors: Issue Date: 2016 Publisher: World Health Organization Place of publication: Geneva

WHO2016

124. Barriers of influenza vaccination intention and behavior: a systematic review of influenza vaccine hesitancy 2005 – 2016

Barriers of influenza vaccination intention and behavior: a systematic review of influenza vaccine hesitancy 2005 – 2016 WHO IRIS: Barriers of influenza vaccination intention and behavior: a systematic review of influenza vaccine hesitancy 2005 – 2016 Browse Related links Files in This Item: File Description Size Format 4.19 MB Adobe PDF Title: Barriers of influenza vaccination intention and behavior: a systematic review of influenza vaccine hesitancy 2005 – 2016 Authors: Issue Date: 2016

WHO2016

125. Pandemic influenza preparedness: sharing of influenza viruses and access to vaccines and other benefits Report by the Director-GeneralPandemic influenza preparedness: sharing of influenza viruses and access to vaccines and other benefits: report by the Di

Pandemic influenza preparedness: sharing of influenza viruses and access to vaccines and other benefits Report by the Director-GeneralPandemic influenza preparedness: sharing of influenza viruses and access to vaccines and other benefits: report by the Di WHO IRIS: Pandemic influenza preparedness: sharing of influenza viruses and access to vaccines and other benefits: report by the Director-General Browse Related links Files in This Item: File Description Size Format 192.17 kB Adobe PDF Title (...) : Pandemic influenza preparedness: sharing of influenza viruses and access to vaccines and other benefits: report by the Director-General Authors: Issue Date: 2016 Publisher: World Health Organization Place of publication: Geneva Language: English Subject: Gov't Doc #: A69/22 URI: Appears in Collections: Items in WHO IRIS are protected by copyright, with all rights reserved, unless otherwise indicated. |

WHO2016

126. Pandemic influenza preparedness: sharing of influenza viruses and access to vaccines and other benefits: report of the Special Session of the Pandemic Influenza Preparedness Framework Advisory Group

Pandemic influenza preparedness: sharing of influenza viruses and access to vaccines and other benefits: report of the Special Session of the Pandemic Influenza Preparedness Framework Advisory Group WHO IRIS: Pandemic influenza preparedness: sharing of influenza viruses and access to vaccines and other benefits: report of the Special Session of the Pandemic Influenza Preparedness Framework Advisory Group Browse Related links Files in This Item: File Description Size Format 184.13 kB Adobe PDF (...) Title: Pandemic influenza preparedness: sharing of influenza viruses and access to vaccines and other benefits: report of the Special Session of the Pandemic Influenza Preparedness Framework Advisory Group Authors: Issue Date: 2016 Publisher: World Health Organization Place of publication: Geneva Language: English Subject: Gov't Doc #: A69/22 Add.1 URI: Appears in Collections: Items in WHO IRIS are protected by copyright, with all rights reserved, unless otherwise indicated. |

WHO2016

127. Pandemic influenza preparedness: sharing of influenza viruses and access to vaccines and other benefits: report by the Director-General

Pandemic influenza preparedness: sharing of influenza viruses and access to vaccines and other benefits: report by the Director-General WHO IRIS: Pandemic influenza preparedness: sharing of influenza viruses and access to vaccines and other benefits: report by the Director-General Browse Related links Files in This Item: File Description Size Format 187.78 kB Adobe PDF Title: Pandemic influenza preparedness: sharing of influenza viruses and access to vaccines and other benefits: report

WHO2016

128. Cohort study: Influenza vaccination and egg allergy: another step forward

Cohort study: Influenza vaccination and egg allergy: another step forward Influenza vaccination and egg allergy: another step forward | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Influenza vaccination and egg allergy: another step forward Article Text Aetiology/Harm Cohort study Influenza vaccination and egg allergy: another step forward Anne Des Roches , Louis Paradis Statistics from Altmetric.com No Altmetric data available for this article. Commentary on: Turner PJ , Southern J , Andrews NJ , et al . Safety of live attenuated influenza vaccine

Evidence-Based Medicine (Requires free registration)2016

129. Immunizations - seasonal influenza

Immunizations - seasonal influenza Immunizations - seasonal influenza - NICE CKS Clinical Knowledge Summaries Share Immunizations - seasonal influenza: Summary Influenza is an acute viral infection of the respiratory tract. Influenza types A and B are responsible for most clinical illness in the UK. In healthy people, seasonal influenza is usually a self-limiting disease with recovery in 2-7 days. However, in older people and those in clinical risk groups, it can result in serious complications (...) such as pneumonia, meningitis, encephalitis, or death. Seasonal influenza immunization is recommended for people at increased risk of complications, including: All people 65 years of age and older. All people aged between 6 months to under 65 years who are in a clinical risk group, such as people with chronic respiratory, heart, kidney, liver, or neurological disease; people with diabetes mellitus; people who are immunosuppressed or immunocompromised, pregnant women, and people with morbid obesity. People

NICE Clinical Knowledge Summaries2016

130. Safety of live attenuated influenza vaccine in young people with egg allergy: multicentre prospective cohort study.

Safety of live attenuated influenza vaccine in young people with egg allergy: multicentre prospective cohort study. STUDY QUESTION: How safe is live attenuated influenza vaccine (LAIV), which contains egg protein, in young people with egg allergy? METHODS: In this open label, phase IV intervention study, 779 young people (2-18 years) with egg allergy were recruited from 30 UK allergy centres and immunised with LAIV. The cohort included 270 (34.7%) young people with previous anaphylaxis to egg

BMJ2015 Full Text: Link to full Text with Trip Pro

131. Nosocomial transmission of avian influenza A (H7N9) virus in China: epidemiological investigation.

Nosocomial transmission of avian influenza A (H7N9) virus in China: epidemiological investigation. STUDY QUESTION: Can avian influenza A (H7N9) virus be transmitted between unrelated individuals in a hospital setting? METHODS: An epidemiological investigation looked at two patients who shared a hospital ward in February 2015, in Quzhou, Zhejiang Province, China. Samples from the patients, close contacts, and local environments were examined by real time reverse transcriptase (rRT) polymerase (...) influenza-like symptoms after sharing the same hospital ward as the index patient for five days. The second patient had not visited any poultry markets nor had any contact with poultry or birds within 15 days before the onset of illness. H7N9 virus was identified in the two patients, who both later died. Genome sequences of the virus isolated from both patients were nearly identical, and genetically similar to the virus isolated from the live poultry market. No specific antibodies were detected among 38

BMJ2015 Full Text: Link to full Text with Trip Pro

132. Maternal vaccination against H1N1 influenza and offspring mortality: population based cohort study and sibling design.

Maternal vaccination against H1N1 influenza and offspring mortality: population based cohort study and sibling design. STUDY QUESTION: What is the mortality in offspring of mothers who had influenza A(H1N1)pdm09 vaccination during pregnancy? METHODS: This was a prospective population based cohort study in seven healthcare regions in Sweden based on vaccinations taking place between 2 October 2009 and 26 November 2010. H1N1 vaccination data were linked with pregnancy and birth characteristics (...) and offspring mortality data in 275,500 births (of which 1203 were stillbirths) from 137,886 mothers. Of these offspring, 41,183 had been exposed to vaccination with Pandemrix, a monovalent AS03 adjuvanted H1N1 influenza vaccine, during fetal life. A primary comparison group consisted of pregnancies of women who were not vaccinated during the same calendar period. In a second comparison, non-exposed siblings of infants prenatally exposed to vaccination were used as controls. Cox regression was used

BMJ2015 Full Text: Link to full Text with Trip Pro

133. Summary of the National Advisory Committee on Immunization (NACI) statement on seasonal influenza vaccine for 2015-2016

Summary of the National Advisory Committee on Immunization (NACI) statement on seasonal influenza vaccine for 2015-2016 CCDR: Volume 41-10, October 1, 2015: Vaccines - Public Health Agency of Canada Public Health Agency of Canada www.publichealth.gc.ca Common menu bar links > > > > CCDR: Volume 41-10, October 1, 2015: Vaccines Share this page To share this page just click on the social network icon of your choice. Canada Communicable Disease Report CCDR ISSN 1481-8531 (On-line) CCDR: Current (...) Issue Additional Resources CCDR: Volume 41-10, October 1, 2015: Vaccines [ ] [ ] [ ] National Advisory Committee Statement Summary of the National Advisory Committee on Immunization (NACI) Statement on Seasonal Influenza Vaccine for 2015‑2016 Gemmill I , , on behalf of the National Advisory Committee on Immunization (NACI) Footnote 1 Chair, NACI Footnote 2 Kingston, Frontenac and Lennox & Addington Public Health, Kingston, ON Correspondence: Abstract Background: The National Advisory Committee

CMA Infobase (Canada)2015

134. Association Between Hospitalization With Community-Acquired Laboratory-Confirmed Influenza Pneumonia and Prior Receipt of Influenza Vaccination.

Association Between Hospitalization With Community-Acquired Laboratory-Confirmed Influenza Pneumonia and Prior Receipt of Influenza Vaccination. IMPORTANCE: Few studies have evaluated the relationship between influenza vaccination and pneumonia, a serious complication of influenza infection. OBJECTIVE: To assess the association between influenza vaccination status and hospitalization for community-acquired laboratory-confirmed influenza pneumonia. DESIGN, SETTING, AND PARTICIPANTS: The Etiology (...) of Pneumonia in the Community (EPIC) study was a prospective observational multicenter study of hospitalizations for community-acquired pneumonia conducted from January 2010 through June 2012 at 4 US sites. In this case-control study, we used EPIC data from patients 6 months or older with laboratory-confirmed influenza infection and verified vaccination status during the influenza seasons and excluded patients with recent hospitalization, from chronic care residential facilities, and with severe

JAMA2015 Full Text: Link to full Text with Trip Pro

135. Early estimation of pandemic influenza Antiviral and Vaccine Effectiveness (EAVE): use of a unique community and laboratory national data-linked cohort study

Early estimation of pandemic influenza Antiviral and Vaccine Effectiveness (EAVE): use of a unique community and laboratory national data-linked cohort study Early estimation of pandemic influenza Antiviral and Vaccine Effectiveness (EAVE): use of a unique community and laboratory national data-linked cohort study Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found (...) . Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> {{metadata.Title}} {{metadata.Headline}} The study has resulted in the creation of a new sentinel system, capable of rapidly determining the estimated incidence of pandemic influenza, and pandemic influenza vaccine and antiviral uptake and effectiveness in preventing influenza and influenza-related clinical outcomes, which is ready

NIHR HTA programme2015 Full Text: Link to full Text with Trip Pro

136. Fact Sheet: Non-pharmaceutical measures to prevent the transmission of influenza

Fact Sheet: Non-pharmaceutical measures to prevent the transmission of influenza NCCEH Fact Sheet: Non-pharmaceutical measures to prevent the transmission of in? uenza This fact sheet is for public health professionals. It provides a brief overview on speci? c non-pharmaceutical measures to be used in community settings. Such measures can prevent the spread of in? uenza by interrupting the transfer of viruses from objects or people through the use of personal protective equipment or changes

National Collaborating Centre for Environmental Health2015

137. Human Infection with a Novel Avian Influenza A(H5N6) Virus.

Human Infection with a Novel Avian Influenza A(H5N6) Virus. Human Infection with a Novel Avian Influenza A(H5N6) Virus. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 26222578 Format MeSH and Other Data E-mail (...) Subject Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2015 Jul 30;373(5):487-9. doi: 10.1056/NEJMc1502983. Human Infection with a Novel Avian Influenza A(H5N6) Virus. 1 , , , . 1 State Key Laboratory of Respiratory Disease, Guangzhou, China. PMID: 26222578 DOI: [Indexed for MEDLINE] Free full text Publication types MeSH terms Full Text Sources Medical PubMed Commons 0

NEJM2015 Full Text: Link to full Text with Trip Pro

138. Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial.

Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial. 26197184 2015 07 22 2015 10 05 2016 10 17 1538-3598 314 3 2015 Jul 21 JAMA JAMA Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial. 237-46 10.1001/jama.2015.7916 Human infections with the avian influenza A(H7N9) virus were first reported (...) of an inactivated H7N9 influenza vaccine, with AS03-adjuvanted formulations inducing the highest titers. This study of 2 adjuvants used in influenza vaccine formulations with adjuvant mixed on site provides immunogenicity information that may be informative to influenza pandemic preparedness programs. clinicaltrials.gov Identifier: NCT01942265. Jackson Lisa A LA Group Health Research Institute, Seattle, Washington. Campbell James D JD Division of Infectious Disease and Tropical Pediatrics, Department

JAMA2015 Full Text: Link to full Text with Trip Pro

139. Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial.

Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial. IMPORTANCE: Human infections with the avian influenza A(H7N9) virus were first reported in China in 2013 and continue to occur. Hemagglutinin H7 administered alone is a poor immunogen necessitating evaluation of adjuvanted H7N9 vaccines. OBJECTIVE: To evaluate the immunogenicity and safety of an inactivated H7N9 vaccine with and without AS03 (...) , 31.7-54.4]; n = 92) and (58.6 [95% CI, 44.3-77.6]; n = 96) than the group induced by 2 AS03-adjuvanted formulations (n = 96) (103.4 [95% CI, 78.7-135.9]; P < .001) but higher GMTs than 2 doses of MF59-adjuvanted formulation (n = 94) (29.0 [95% CI, 22.4-37.6]; P < .001). CONCLUSIONS AND RELEVANCE: The AS03 and MF59 adjuvants augmented the immune responses to 2 doses of an inactivated H7N9 influenza vaccine, with AS03-adjuvanted formulations inducing the highest titers. This study of 2

JAMA2015

140. Population-level susceptibility, severity and spread of pandemic influenza: design of, and initial results from, a pre-pandemic and hibernating pandemic phase study using cross-sectional data from the Health Survey for England (HSE)

Population-level susceptibility, severity and spread of pandemic influenza: design of, and initial results from, a pre-pandemic and hibernating pandemic phase study using cross-sectional data from the Health Survey for England (HSE) Population-level susceptibility, severity and spread of pandemic influenza: design of, and initial results from, a pre-pandemic and hibernating pandemic phase study using cross-sectional data from the Health Survey for England (HSE) Journals Library An error has

NIHR HTA programme2015 Full Text: Link to full Text with Trip Pro